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Abstract	
Frontotemporal	 dementia	 (FTD)	 is	 a	 clinically	 and	 neuroanatomically	 heterogeneous	
neurodegenerative	disorder	with	multiple	underlying	genetic	and	pathological	causes.	Whilst	 initial	
neuroimaging	 studies	 highlighted	 the	 presence	 of	 frontal	 and	 temporal	 lobe	 atrophy	 or	
hypometabolism	as	 the	unifying	 feature	 in	patients	with	FTD,	more	detailed	studies	have	revealed	
diverse	 patterns	 across	 individuals,	 with	 variable	 frontal	 or	 temporal	 predominance,	 differing	
degrees	 of	 asymmetry,	 and	 the	 involvement	 of	 other	 cortical	 areas	 including	 the	 insula	 and	
cingulate,	as	well	as	subcortical	structures	such	as	the	basal	ganglia	and	thalamus.	Recent	advances	
in	 novel	 imaging	 modalities	 including	 diffusion	 tensor	 imaging,	 resting-state	 functional	 MRI	 and	
molecular	PET	 imaging	allow	 the	possibility	of	 investigating	alterations	 in	 structural	and	 functional	
connectivity	and	the	visualisation	of	pathological	protein	deposition.	This	review	will	cover	the	major	
imaging	modalities	currently	used	in	research	and	clinical	practice,	focusing	on	the	key	insights	they	
have	 provided	 into	 FTD,	 including	 the	 onset	 and	 evolution	 of	 pathological	 changes	 and	 also	
importantly	 their	utility	as	biomarkers	 for	disease	detection	and	staging,	differential	diagnosis	and	
measurement	 of	 disease	 progression.	 Validating	 neuroimaging	 biomarkers	 that	 are	 able	 to	
accomplish	 these	 tasks	will	be	crucial	 for	 the	ultimate	goal	of	powering	upcoming	clinical	 trials	by	
correctly	stratifying	patient	enrolment	and	providing	sensitive	markers	for	evaluating	the	effects	and	
efficacy	of	disease-modifying	therapies.	
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Introduction	
Frontotemporal	 dementia	 (FTD)	 is	 a	 clinically,	 genetically	 and	 pathologically	 heterogeneous	
neurodegenerative	 disorder	 (Seelaar	 et	 al.,	 2011)	 and	 a	 common	 cause	 of	 early	 onset	 dementia	
(Onyike	 &	 Diehl-Schmid,	 2013).	 Clinically,	 patients	 present	 with	 either	 changes	 in	 behaviour	 and	
personality	(behavioural	variant	FTD,	bvFTD),	or	language	impairment	(primary	progressive	aphasia,	
PPA).	 PPA	 can	 be	 further	 divided	 into	 three	 main	 subtypes,	 semantic	 variant	 (svPPA),	 nonfluent	
variant	 (nfvPPA),	 and	 logopenic	 variant	 (lvPPA)	 (Gorno-Tempini	 et	 al.,	 2011).	 As	 the	 disease	
progresses,	 patients	 may	 also	 develop	 features	 of	 amyotrophic	 lateral	 sclerosis	 (FTD-ALS),	
corticobasal	 syndrome	 (CBS)	 or	 progressive	 supranuclear	 palsy	 (PSP).	 FTD	 is	 highly	 heritable,	with	
approximately	 a	 third	 of	 patients	 exhibiting	 an	 autosomal	 dominant	 form:	 mutations	 in	 the	
microtubule-associated	 protein	 tau	 (MAPT)	 and	 progranulin	 (GRN)	 genes	 and	 hexanucleotide	
expansions	in	the	chromosome	9	open	reading	frame	72	(C9orf72)	gene	constitute	the	major	causes	
(Rohrer	et	al.,	2009a).	Pathologically,	neuronal	 inclusions	usually	contain	abnormal	forms	of	one	of	
three	proteins:	tau,	TAR	DNA-binding	protein	43	(TDP-43)	or	fused	in	sarcoma	(FUS)	 (Mackenzie	et	
al.,	2010).		
Early	neuroimaging	studies	quantifying	atrophy	from	volumetric	magnetic	resonance	imaging	(MRI)	
and	 hypometabolism	 using	 18F-fluorodeoxyglucose	 positron	 emission	 tomography	 (FDG-PET)	
revealed	 characteristic	 patterns	 of	 abnormalities	 across	 FTD	 subtypes,	 whilst	 recent	 advances	 in	
novel	imaging	modalities	such	as	diffusion	tensor	imaging	(DTI),	resting-state	functional	MRI,	arterial	
spin	 labelling	 (ASL)	 and	 tau	 PET	 imaging	 provide	 promising	 new	 techniques	 for	 investigating	
connectivity	and	molecular	changes	in	these	clinical,	genetic	and	pathological	subgroups.	This	review	
will	cover	the	major	imaging	modalities	currently	used	in	research	and	clinical	practice,	focusing	on	
the	 key	 insights	 they	 have	 provided	 into	 FTD,	 including	 the	 onset	 and	 evolution	 of	 pathological	
changes	 and	 also	 importantly	 their	 utility	 as	 biomarkers	 for	 disease	 detection	 and	 staging,	
differential	diagnosis	and	measurement	of	disease	progression.	Validating	neuroimaging	biomarkers	
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that	are	able	 to	accomplish	 these	tasks	will	be	crucial	 for	 the	ultimate	goal	of	powering	upcoming	
clinical	trials	by	correctly	stratifying	patient	enrolment	and	providing	sensitive	markers	for	evaluating	
the	effects	and	efficacy	of	disease-modifying	therapies.		
	
Neuroanatomical	signatures	of	FTD	
1.	Differing	distributions:	visualising	structural	loss	using	volumetric	3D	T1	MRI	
There	 is	a	considerable	body	of	 research	employing	volumetric	MRI	 to	 investigate	 the	pattern	and	
distribution	of	cerebral	loss	(often	with	a	focus	on	grey	matter)	in	FTD.	The	majority	of	studies	have	
been	 aimed	 at	 improving	 differential	 diagnosis,	 both	 distinguishing	 FTD	 from	 other	
neurodegenerative	conditions	 such	as	Alzheimer’s	disease	 (AD),	as	well	as	differentiating	between	
the	clinical,	pathological	and	genetic	subtypes	within	the	FTD	spectrum.	
Clinical	syndromes	
Volume	loss	in	bvFTD	occurs	primarily	in	the	frontal	and	temporal	lobes.	Several	meta-analyses	have	
highlighted	the	particular	involvement	of	the	prefrontal	cortex,	anterior	temporal	regions,	the	insula,	
anterior	 cingulate,	 striatum	 and	 thalamus	 (Figure	 1)	 (Pan	 et	 al.,	 2012;	 Schroeter	 et	 al.,	 2007),	 a	
pattern	 that	 has	 high	 sensitivity	 and	 specificity	 in	 differentiating	 bvFTD	 from	AD	 (Schroeter	 et	 al.,	
2007).	Despite	a	general	 consensus	 in	 the	 regional	pattern	of	 involvement	at	 the	group	 level,	one	
important	 issue	 is	 the	 significant	heterogeneity	of	 individual	 findings,	with	 cases	having	a	 variable	
degree	of	hemispheric	asymmetry,	differing	predominance	of	frontal	versus	temporal	 lobe	atrophy	
and	a	varying	extent	of	posterior	cortical	involvement	(Schroeter	et	al.,	2014).	To	address	this,	two	
cluster	analyses	have	been	performed,	which	suggest	that	at	least	four	neuroanatomical	subtypes	of	
bvFTD	 exist:	 two	 with	 predominantly	 frontal	 atrophy	 (a	 focal	 frontal-dominant	 and	 a	 more	
distributed	frontotemporal	subtype)	and	two	with	predominantly	temporal	involvement	(including	a	
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focal	 temporal-dominant	 and	 a	 more	 widespread	 temporo-frontal-parietal	 subtype),	 which	
potentially	map	onto	distinct	pathogenetic	causes	of	FTD	(Whitwell	et	al.,	2009b,	2012).	
In	 contrast,	 svPPA	patients	have	a	much	more	 characteristic	pattern	of	 asymmetric	 temporal	 lobe	
atrophy,	 primarily	 in	 the	 anterior	 and	 inferior	 regions	 (Gorno-Tempini	 et	 al.,	 2004;	 Rohrer	 et	 al.,	
2009b).	The	most	common	presentation	is	prominent	left-sided	atrophy,	although	a	right-dominant	
variant	 has	 been	described	 (Chan	et	 al.,	 2009;	 Josephs	 et	 al.,	 2009).	 Earliest	 changes	 include	 grey	
matter	 loss	 in	the	inferior	temporal	and	fusiform	gyri,	the	temporal	pole	and	the	parahippocampal	
and	entorhinal	cortex	 (Figure	1)	 (Brambati	et	al.,	2009;	Rogalski	et	al.,	2011;	Rohrer	et	al.,	2009b).	
These	 changes	 can	 be	 striking	 at	 presentation	 with	 the	 MRI	 revealing	 advanced	 temporal	 pole	
atrophy	 despite	 the	 patient’s	 general	maintenance	 of	 activities	 of	 daily	 living.	 Involvement	 of	 the	
amygdala	and	hippocampus	has	also	been	reported	(Schroeter	et	al.,	2007).	With	increasing	severity,	
this	pattern	extends	anteriorly	to	include	orbitofrontal,	inferior	frontal,	insular	and	anterior	cingulate	
cortices,	as	well	as	posteriorly	to	include	temporoparietal	regions,	and	corresponding	regions	in	the	
contralateral	hemisphere	(Rohrer	et	al.,	2009b).		
Atrophy	 profiles	 in	 nfvPPA	 also	 include	 predominantly	 left	 hemisphere	 cortical	 regions	 of	 loss;	
however,	 the	 distribution	 distinguishes	 it	 from	 svPPA	 (Gorno-Tempini	 et	 al.,	 2004;	 Rogalski	 et	 al.,	
2011).	 These	 include	 changes	 in	 the	 inferior	 frontal	 gyrus	 (IFG),	 (particularly	 the	pars	opercularis),	
dorsolateral	prefrontal	cortex	(DPFC),	superior	temporal	gyrus	and	insula	(Figure	1).	Over	time,	this	
pattern	of	cortical	 loss	 includes	prefrontal	and	temporal	 lobe	structures	 in	the	right	hemisphere	as	
well	 as	 continued	 propagation	 ipsilaterally	 to	 encompass	 anterior	 frontal,	 lateral	 temporal	 and	
anterior	parietal	lobes	(Rogalski	et	al.,	2011;	Rohrer	et	al.,	2009b),	with	involvement	of	caudate	and	
putamen	bilaterally	(Gorno-Tempini	et	al.,	2004).		
In	 contrast	 to	 both	 svPPA	 and	 nfvPPA,	 the	 logopenic	 variant	 of	 PPA	 presents	 with	 a	 significantly	
more	posterior	profile,	involving	early	left	temporoparietal	and	posterior	cingulate	atrophy	(Gorno-
Tempini	et	al.,	2004;	Rogalski	et	al.,	2011)	(Figure	1).	
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In	 summary,	 investigations	 based	 on	 clinical	 syndromes	 have	 proven	 useful	 in	 elucidating	 broadly	
distinct	and	dissociable	patterns	of	atrophy	that	correspond	well	with	the	behavioural	and	language	
disturbances	 that	 are	 associated	with	 the	 syndromes.	 However,	 considerable	 individual	 variability	
within	these	groups	and	some	overlap	of	regional	involvement	occurs,	likely	reflecting	the	significant	
heterogeneity	of	genetic	contributions	and	pathological	processes	underpinning	the	disease.	When	
this	information	is	available,	investigations	including	these	levels	of	classification	have	proved	highly	
valuable	in	extending	our	understanding	of	FTD.	
Genetic	forms	
Patients	 with	 MAPT	 mutations	 present	 primarily	 with	 focal	 symmetrical	 anterior	 temporal	 and	
orbitofrontal	 lobe	 atrophy	 (Figure	 2).	 Caudate,	 insula	 and	 anterior	 cingulate	 involvement	 has	 also	
been	 reported	 (Ghetti	 et	 al.,	 2015;	 Spina	 et	 al.,	 2008).	 In	 addition,	 preliminary	 findings	 suggest	 a	
more	lateral	temporal	lobe	signature	for	MAPT	mutations	in	the	coding	region,	while	those	affecting	
the	 splicing	 of	 exon	 10	 target	 the	medial	 temporal	 lobes	 (Whitwell	 et	 al.,	 2009a).	 In	 these	 latter	
cases,	the	marked	symmetrical	 loss	of	hippocampal	volume	may	cause	confusion	with	AD	(Liang	et	
al.,	 2014;	 Tolboom	 et	 al.,	 2010).	 Unlike	MAPT,	GRN	 mutations	 commonly	 present	 with	markedly	
asymmetric	atrophy	of	the	temporal,	inferior	frontal	and	inferior	parietal	lobes	(Rohrer	et	al.,	2010b;	
Whitwell	 et	 al.,	 2012).	 Finally,	 C9orf72	 mutations	 show	 a	 more	 distributed	 symmetric	 pattern	 of	
atrophy,	 predominantly	 involving	 dorsolateral	 and	 medial	 frontal	 and	 orbitofrontal	 lobes,	 with	
additional	 loss	 in	 anterior	 temporal,	 parietal	 and	 occipital	 lobes,	 as	 well	 as	 in	 the	 thalamus	 and	
cerebellum	 (Mahoney	 et	 al.,	 2012;	 Sha	 et	 al.,	 2012).	 These	 atrophy	 profiles	 not	 only	 differentiate	
MAPT,	GRN	and	C9orf72	patients	at	the	group	level	but	have	shown	some	success	in	classifying	the	
different	mutation	carriers	at	the	single-subject	level	(Whitwell	et	al.,	2012).	
Pathologically	defined	forms	
Given	that	future	therapeutic	interventions	will	likely	target	the	abnormal	proteins	underpinning	the	
disease,	a	key	challenge	is	finding	neuroanatomical	signatures	that	can	accurately	predict	molecular	
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pathology	 non-invasively	 during	 life.	 Recent	 advances	 in	 classifying	 the	 subtypes	 of	 these	 FTD	
pathologies	have	contributed	greatly	to	this	goal	(Figure	2).	In	the	tauopathies,	Pick’s	disease	can	be	
associated	 with	 often	 striking	 asymmetric	 atrophy	 in	 the	 frontal	 cortex,	 (including	 orbitofrontal,	
medial,	 and	 dorsolateral	 regions	 primarily),	 with	 involvement	 of	 the	 anterior	 temporal	 lobes	 and	
insula	as	well	(Rankin	et	al.,	2011;	Whitwell	et	al.,	2011a).	PSP	is	associated	classically	with	midbrain	
atrophy	 (Massey	 et	 al.,	 2013);	 however,	 despite	 being	 relatively	 specific	 this	 is	 not	 a	 sensitive	
marker.	Moreover,	in	patients	with	cognitive	presentations,	PSP	and	CBD	tauopathies	are	associated	
with	more	 posterior	 frontal	 cortical	 atrophy,	 targeting	 the	 supplementary	 and	 pre-motor	 regions,	
with	 CBD	 showing	 a	 more	 asymmetric	 and	 distributed	 pattern	 including	 the	 parietal	 lobes	 and	
striatum	(Josephs	et	al.,	2008;	Whitwell	et	al.,	2010a).	
TDP-43	 proteinopathies	 can	 be	 divided	 into	 four	 distinct	 subtypes	 (Types	 A–D),	 based	 on	
morphology	 of	 the	 inclusions	 (Mackenzie	 et	 al.,	 2011).	 Patients	with	TDP-A	 pathology	 (commonly	
associated	 with	 GRN	 mutations)	 present	 with	 widespread	 asymmetric	 fronto-temporo-parietal	
atrophy	 (Rohrer	 et	 al.,	 2010a;	 Whitwell	 et	 al.,	 2010b),	 with	 anterior	 cingulate	 and	 caudate	
involvement	 (Rohrer	et	al.,	2011).	TDP-B	patients	present	with	 symmetrical	 frontal	 lobe	as	well	as	
insula	 and	 anteromedial	 temporal	 lobe	 atrophy,	 whilst	 in	 contrast,	 TDP-C	 patients	 show	
asymmetrical	 loss	 in	 the	 anteroinferior	 temporal	 lobe,	 consistent	 with	 the	 predominant	 clinical	
diagnosis	of	 svPPA	 (Rohrer	&	Rosen,	2013).	TDP-D	 is	by	 far	 the	 rarest	 variant	and	associated	with	
mutations	 in	 the	 valosin-containing	 protein	 (VCP)	 gene.	 Preliminary	 MRI	 findings	 have	 been	
inconsistent	 and	 failed	 to	 demonstrate	 a	 clear	 pattern	 (Kim	 et	 al.,	 2011;	 Stojkovic	 et	 al.,	 2009;	
Surampalli	et	al.,	2015).		
Although	 rare,	 investigations	 into	 FUS	 pathology	 cases	 reveal	 a	 pattern	 of	 atrophy	 affecting	 the	
orbitofrontal	 lobe,	 anteromedial	 temporal	 lobe,	 anterior	 cingulate,	 insula	 and	 particularly	 striking	
caudate	atrophy	(Figure	2)	(Josephs	et	al.,	2010;	Rohrer	et	al.,	2011;	Seelaar	et	al.,	2010).	
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In	summary,	structural	imaging	provides	a	valuable	tool	for	capturing	neuroanatomical	signatures	in	
the	clinical,	genetic	and	pathological	subgroups	of	FTD.	The	profiles	commonly	correspond	well	with	
the	clinical	presentation	and	despite	overlap	provide	useful	tools	for	differentiating	subtypes	at	the	
group,	 and	 in	 some	 cases	 individual,	 subject	 level.	However,	 inconsistencies	 in	 the	 literature	 exist	
and	 volumetric	 MRI	 changes	 may	 well	 be	 visible	 only	 after	 significant	 neuronal	 loss.	 In	 contrast,	
measures	 of	 regional	 brain	 activity	 may	 provide	 greater	 sensitivity	 to	 degenerative	 disease	 by	
detecting	deterioration	of	neuronal	function	prior	to	cell	loss	(Jack	et	al.,	2010).	
	 	 	
2.	A	loss	of	connection	Part	1:	viewing	functional	networks	with	resting-state	fMRI	
There	is	increasing	focus	on	network-led	frameworks	for	understanding	the	distribution	and	impact	
of	 neurodegeneration.	 Resting-state	 fMRI	 can	 be	 used	 to	 elucidate	 functionally	 connected	 brain	
networks	 by	 measuring	 synchronised	 time-dependent	 fluctuations	 in	 blood	 oxygenation	 levels	
(BOLD	signal)	as	a	surrogate	measure	of	co-ordinated	neural	activity.	Different	patterns	of	correlated	
activation	can	detect	spatially	distinct,	but	functionally	related	networks	of	cortical	and	subcortical	
regions	 (Seeley	et	 al.,	 2009).	 The	 key	 functional	 networks	 implicated	 in	 FTD	are	 the	default	mode	
network,	the	language	and	semantic	networks	distributed	predominantly	across	the	left	hemisphere,	
and	the	salience	network	(Figure	3)	(Pievani	et	al.,	2011;	Lee	et	al.,	2014).	In	bvFTD,	multiple	studies	
have	 described	 reduced	 connectivity	 in	 the	 salience	 network,	 which	 includes	 the	 frontal	 lobe,	
anterior	 cingulate,	 insula,	 amygdala,	medial	 thalamus	 and	 ventral	 striatum,	 all	 regions	 involved	 in	
evaluating	 emotional	 significance	 and	 appropriately	 contextualising	 responses	 (Farb	 et	 al.,	 2013;	
Seeley	 et	 al.,	 2007).	 It	 has	 been	 proposed	 that	 reduced	 connectivity	 in	 the	 salience	 network	may	
result	in	compensatory	increased	connectivity	within	the	default	mode	network	(Borroni	et	al.,	2012;	
Farb	 et	 al.,	 2013;	Whitwell	 et	 al.,	 2011b;	 Zhou	 et	 al.,	 2010).	 However,	 this	 finding	 has	 not	 been	
consistent	across	all	studies	of	bvFTD	patients	(Filippi	et	al.,	2013;	Rohrer	&	Rosen,	2013).	In	svPPA,	
reduced	functional	connectivity	particularly	affecting	a	semantic	network	involving	the	left	anterior	
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temporal	 lobe	 has	 been	 shown	 (Guo	 et	 al.,	 2013),	 along	 with	 inferior	 and	 ventral	 regions	 of	 the	
temporal	 lobe,	 bilateral	 frontal	 cortex,	 left	 amygdala,	 hippocampus,	 caudate	 and	 occipital	 regions	
(Agosta	et	al.,	2014).	Despite	few	investigations	of	nfvPPA,	there	is	preliminary	evidence	for	reduced	
functional	 connectivity	 in	 the	 frontal	 operculum,	 primary	 and	 supplementary	 motor	 areas	 and	
inferior	parietal	 lobule,	 linking	the	language	and	motor	networks	that	enable	fluent	speech	(Seeley	
et	al.,	2009)	
In	summary,	studies	on	functional	connectivity	in	FTD	demonstrate	that	anatomical	regions	affected	
by	 specific	phenotypes	 show	abnormalities	 in	 related	 functional	 connectivity	networks.	Whilst	 the	
use	of	resting-state	 fMRI	has	proven	robust	 in	differentiating	bvFTD	from	AD	patients	 (Zhou	et	al.,	
2010;	Zhou	&	Seeley,	2014),	more	work	is	required	in	comparing	clinical	subtypes	and	in	genetic	and	
pathologically	confirmed	cohorts	to	improve	the	utility	of	this	promising	technique	in	FTD.	
	
3.	 A	 loss	 of	 connection	 Part	 2:	 structural	 connectivity	 investigations	with	 diffusion	 tensor	 imaging	
(DTI)	
Investigating	alterations	in	key	white	matter	structural	connections	(Figure	4)	is	of	particular	interest	
in	understanding	propagation	of	neurodegeneration	(Warren	et	al.,	2013).	Diffusion	tensor	imaging	
(DTI)	 allows	 the	 visualisation	 of	 these	 structural	 networks	 by	 measuring	 directionality	 (fractional	
anisotropy)	 and	 level	 of	 diffusivity	 (mean,	 radial	 and	 axial)	 of	 water	 in	 the	 brain.	Water	 diffuses	
differently	depending	on	 tissue	 type,	neural	 integrity	and	presence	of	barriers	 such	as	myelinated	
fibres,	 enabling	modelling	 of	 the	 architecture	 of	 neuronal	 connections	 (Soares	 et	 al.,	 2013).	 High	
fractional	 anisotropy	 (FA)	 indicates	 intact	 connected	 fibres,	 as	 water	 diffusion	 is	 restricted	
directionally	 along	 these	 tracts.	 A	 decrease	 in	 FA	 and	 increase	 in	 diffusivity	 therefore	 suggests	
degeneration	of	these	directional	fibres	and	loss	of	structural	connectivity	within	the	brain.		
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In	bvFTD,	patients	present	with	widespread	reduction	in	FA	and	increased	diffusivity	metrics	in	tracts	
with	 reciprocal	 connections	 to	 the	 frontal	 and	 temporal	 lobes.	 Key	 tracts	 include	 the	 uncinate	
fasciculus,	 the	 genu	 of	 the	 corpus	 callosum	 (with	 an	 anterior-posterior	 gradient)	 and	 cingulum	
(Agosta	 et	 al.,	 2012;	Mahoney	 et	 al.,	 2015).	 Alterations	 in	 the	 anterior	 parts	 of	 the	 superior	 and	
inferior	longitudinal	fasciculi	and	inferior	fronto-occipital	fasciculus	have	also	been	reported	(Diehl-
Schmid	et	al.,	2014),	connecting	grey	matter	regions	shown	to	be	predominantly	atrophied	in	bvFTD	
and	implicated	in	the	key	behavioural	symptoms	(Cerami	&	Cappa,	2013).	
For	 bvFTD	 patients	 with	 a	MAPT	 mutation,	 the	 cingulum	 and	 uncinate	 fasciculus	 are	 particularly	
affected	(Mahoney	et	al.,	2014).	Uncinate	fasciculus	abnormalities	have	also	been	demonstrated	in	
presymptomatic	 MAPT	 mutation	 carriers	 (Dopper	 et	 al.,	 2013)	 suggesting	 a	 particular	 early	
vulnerability	 in	 these	 tracts.	 In	C9orf72	mutation	 carriers,	 FA	 reductions	 have	 been	 shown	 in	 the	
superior	cerebellar	peduncles,	in	line	with	previous	findings	of	cerebellar	atrophy	in	C9orf72	patients	
(Mahoney,	et	al.,	2012),	a	region	previously	thought	to	be	relatively	preserved	in	FTD.	
The	 PPA	 groups	 show	 more	 focal	 and	 asymmetric	 white	 matter	 changes	 in	 specific	 networks	
fundamental	 to	 language	 processing.	 In	 svPPA,	 left	 frontotemporal	 abnormalities	 dominate,	
including	the	left	uncinate	fasciculus	and	inferior	longitudinal	fasciculus	tracts	(Mahoney	et	al.,	2013;	
Tu	 et	 al.,	 2016).	 Additional	 regions	 include	 corpus	 callosum	 and	 cingulum,	 with	 sparing	 of	 the	
occipital	 white	 matter,	 brainstem,	 and	 cerebellum	 (Agosta,	 et	 al.,	 2012;	 Galantucci	 et	 al.,	 2011).	
Decreased	FA	and	increased	diffusivity	is	somewhat	more	distributed	in	nfvPPA	with	predominantly	
left	 frontotemporoparietal	 abnormalities.	 Tracts	 and	 subcomponents	 affected	 include	 the	 left	
superior	 longitudinal	 fasciculus,	 the	 corpus	 callosum,	 left	 cingulum,	 left	 orbitofrontal,	 inferior	
frontal,	anterior	temporal,	and	inferior	parietal	white	matter	regions	(Agosta	et	al.,	2012;	Galantucci	
et	al.,	2011).	In	keeping	with	the	distribution	of	grey	matter	volume	loss,	white	matter	abnormalities	
in	 lvPPA	 variants	 demonstrate	 left	 frontoparietal	 predominance,	 including	 the	 left	 superior	
longitudinal	fasciculus/arcuate	fasciculus	particularly	(Agosta	et	al.,	2012).	
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DTI	measures	show	promise	 in	sensitivity	analyses	for	differentiating	FTD	from	control	subjects,	as	
well	 as	 between	 the	 subgroups.	 However,	 there	 is	 some	 inconsistency	 in	 precisely	 which	
combination	 of	 DTI	 metrics	 and	 tracts	 produces	 the	 best	 predictors	 and	 will	 need	 further	
investigation	to	improve	utility	as	a	marker	for	differential	diagnosis	(Agosta	et	al.,	2012;	Mahoney	
et	 al.,	 2015).	DTI	metrics	 also	 show	promise	as	markers	 identifying	earliest	pathogenic	 changes	 in	
FTD.	 The	 key	 white	 matter	 tracts	 demonstrating	 abnormalities	 are	 connected	 to	 regions	 of	
significant	 grey	matter	 loss	 in	 the	 syndromic	 variants,	 but	often	more	extensively,	 suggesting	 that	
alterations	 in	 white	 matter	 integrity	 precede	 structural	 changes.	 This	 is	 further	 supported	 by	
presymptomatic	studies	detecting	white	matter	changes	in	the	absence	of	grey	matter	abnormalities	
(Borroni	et	al.,	2008;	Dopper	et	al.,	2013).	Further	 investigation	 including	pathologically	confirmed	
and	 larger	 cohorts	 of	 genetic	 presymptomatic	 patients	 will	 strengthen	 the	 current	 findings	 and	
determine	the	best	method	for	measuring	the	earliest	change.	In	addition,	valid	methods	for	pooling	
findings	 into	meta-analyses	of	DTI	data	are	currently	 lacking	and	will	be	highly	valuable	for	further	
clarification	of	findings.	
	
4.	Altered	uptake:	imaging	loss	of	metabolism		
PET	 with	 [18F]	 fluorodeoxyglucose	 (FDG-PET)	 and	 perfusion	 single-photon	 emission	 computed	
tomography	 (SPECT)	 are	 widely	 utilised	 methods	 for	 investigating	 patterns	 of	 cerebral	 glucose	
metabolism	or	cerebral	perfusion	as	measures	of	neuronal	(dys)function.	FDG-PET	has	been	found	to	
have	greater	utility	than	SPECT	(Davison	&	O’Brien,	2014).	The	patterns	of	hypometabolism	tend	to	
accord	closely	with	patterns	of	atrophy	(Figure	5).	Numerous	FDG-PET	studies,	including	those	with	
post-mortem	 pathological	 confirmation	 demonstrate	 high	 sensitivity	 and	 specificity	 in	 aiding	
differential	diagnosis	of	AD	and	FTD	(Davison	&	O’Brien,	2014;	Foster	et	al.,	2007;	Panegyres	et	al.,	
2009;	Rabinovici	et	al.,	2011)	as	well	as	promise	in	differentiating	FTD	subtypes	(Matias-Guiu	et	al.,	
2014).	 Hypometabolism	 in	 the	 frontotemporal	 regions	 is	 commonly	 found	 in	 bvFTD	 patients,	
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particularly	 affecting	 the	 orbitofrontal,	 dorsolateral	 and	 medial	 prefrontal	 cortex	 and	 anterior	
temporal	 poles	 (Diehl-Schmid	 et	 al.,	 2007;	 Ishii,	 2014;	 Verfaillie	 et	 al.,	 2015).	 Involvement	 of	 the	
hippocampus,	 anterior	 cingulate,	 basal	 ganglia,	 anterior	 insula	 and	 thalamus	 have	 been	 less	
consistently	reported,	most	likely	due	to	variability	in	techniques,	underlying	pathology	and	disease	
severity	between	studies	(Mosconi	et	al.,	2008;	Schroeter	et	al.,	2007).	In	svPPA	patients,	temporal	
lobe	 hypometabolism	 predominates,	 with	 asymmetrical	 left	 hemisphere	 involvement	 in	 the	
entorhinal	and	perirhinal	cortex,	inferior	temporal	poles	and	amygdala	(Desgranges	et	al.,	2007).	For	
nfvPPA	patients,	more	pronounced	hypometabolism	is	evident,	particularly	in	the	left	inferior	frontal	
and	superior	temporal	regions	(Rabinovici	et	al.,	2008).	Finally,	lvPPA	subjects	show	distributed	left	
frontotemporoparietal	 hypometabolism,	 particularly	 involving	 lateral	 frontal	 and	 posterior-lateral	
temporal	lobes,	alongside	caudate,	posterior	cingulate	and	precuneus	regions	(Josephs	et	al.,	2014;	
Madhavan	et	al.,	2013;	Rabinovici	et	al.,	2008).	
In	summary,	FDG-PET	and	SPECT	have	been	widely	used	to	assess	regional	metabolic	changes	in	FTD	
and	have	value	 in	differential	diagnosis	and	early	detection	of	pathogenic	abnormalities.	However,	
the	degree	of	overlap	of	hypometabolism	across	the	FTD	spectrum	and	how	distinct	patterns	map	
onto	 particular	 genetic	 and	 pathological	 subtypes	 is	 not	 well	 understood	 and	will	 require	 further	
investigation.	Despite	 its	advantages,	FDG-PET	 involves	exposure	to	 ionizing	radiation,	 is	expensive	
and	 is	 not	 widely	 available,	 which	 limits	 its	 clinical	 utility.	 There	 are	 also	 methodological	 issues	
regarding	correction	for	atrophy/partial	volume	effects	during	analysis.	An	alternative	for	measuring	
regional	cerebral	dysfunction	is	arterial	spin	labelling	(ASL)	MRI	to	assess	cerebral	blood	flow	(CBF)	
deficits.	
	
5.	Patterns	of	perfusion:	arterial	spin	labelling	(ASL)	demonstrates	altered	cerebral	blood	flow	
Although	currently	underutilised,	ASL	imaging	can	be	used	to	assess	CBF	using	magnetically	labelled	
arterial	blood	H2O	as	an	endogenous	marker.	Advantages	 include	 relatively	 short	acquisition	 time,	
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no	exposure	 to	 radiation,	 non-invasiveness,	 relatively	 low	 cost	 and	wide	availability.	As	with	 FDG-
PET,	 the	 majority	 of	 investigations	 have	 been	 focused	 on	 investigating	 its	 utility	 in	 differential	
diagnosis	of	FTD	from	AD	(Binnewijzend	et	al.,	2014).	Patients	with	bvFTD	show	bilateral	frontal	and	
anterior	 cingulate	 hypoperfusion,	 whereas	 AD	 patients	 present	 with	 a	 more	 posterior	 profile	
including	the	medial	parietal	regions,	posterior	cingulate	and	the	precuneus	(Hu	et	al.,	2010;	Shimizu	
et	 al.,	 2010).	 The	presence	of	 posterior	 cingulate	hypoperfusion	has	 recently	 been	 shown	 to	be	 a	
sensitive	 early	 stage	 differential	 diagnostic	 marker	 in	 separating	 AD	 from	 bvFTD	 (Steketee	 et	 al.,	
2015).	In	general,	the	patterns	detected	correlate	well	with	changes	in	metabolism	(Verfaillie	et	al.,	
2015)	 and	 thus	 ASL	 shows	 promise	 as	 a	 future	 alternative	 to	 FDG-PET,	 particularly	 in	multimodal	
imaging	approaches,	although	similar	methodological	issues	to	FDG-PET	exist	in	analysing	ASL	data.	
To	 date,	 only	 a	 few	 studies	 utilising	 ASL	 in	 FTD	 and	 combined	 ASL/FDG-PET	 investigations	 exist,	
therefore	 further	 investigations	 are	 required	 to	 confirm	 the	 utility	 of	 ASL	 as	 a	 biomarker	 for	
differential	diagnosis	at	the	subgroup	and	individual	subject	level	in	FTD.	
The	 imaging	modalities	discussed	thus	far	provide	 insights	 into	phenotypic	and	genotypic	grey	and	
white	 matter	 neuroanatomical	 signatures	 of	 disease.	 However,	 with	 few	 cases	 coming	 to	 post-
mortem	 examination,	 much	 is	 still	 unknown	 about	 how	 these	 presentations	 map	 onto	 the	
underlying	pathology	driving	the	disease	process.	Deducing	histopathology	in	patients	often	relies	on	
a	probabilistic	combination	of	clinical	features,	neuroanatomical	profile	and	what	is	currently	known	
about	the	distribution	of	pathological	burden.	This	model	may	prove	useful	at	the	group	 level,	but	
prediction	of	single	subject	pathology	is	more	difficult.	Whilst	definitive	diagnosis	can	only	be	made	
from	 histopathological	 examination	 of	 brain	 tissue,	 molecular	 imaging	 provides	 a	 promising	
alternative	to	identifying	pathology	in	vivo.	
	
6.	Molecular	imaging	of	the	moment:	the	place	of	amyloid	positron	emission	tomography	(PET)		
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The	development	of	PET-based	imaging	tracers,	which	bind	to	and	thus	demonstrate	distribution	of	
abnormal	aggregations	of	amyloid	in	the	brain,	has	proved	valuable	in	visualising	neuropathology	in	
vivo.	Several	studies	have	shown	the	diagnostic	utility	of	amyloid	imaging	in	assisting	differentiation	
of	AD	from	FTD	with	relatively	high	sensitivity	and	specificity	given	that	Aβ	plaques	are	a	hallmark	of	
AD	and	not	within	the	FTD	pathologic	spectrum	(Drzezga	et	al.,	2008;	Engler	et	al.,	2008;	Rabinovici	
et	al.,	2011;	Villemagne	et	al.,	2011).	Most	FTD	patients	reveal	negative	imaging	findings	for	Aβ,	with	
the	notable	 exception	of	 lvPPA	patients	who	usually	 have	underlying	AD	pathology	 and	 therefore	
have	amyloid	tracer	retention	(Figure	6)	(Leyton	et	al.,	2011;	Mesulam	et	al.,	2014).	Several	studies	
have	also	 reported	a	 small	percentage	of	bvFTD,	 svPPA	and	nfvPPA	patients	with	positive	amyloid	
PET	 scans	 (Engler	 et	 al.,	 2008;	 Rabinovici	 et	 al.,	 2008;	 Villemagne	 et	 al.,	 2011).	 Classification	was	
based	 on	 clinical	 diagnosis	 and	 thus	 without	 histopathological	 confirmation	 the	 positive	 imaging	
findings	in	FTD	may	reflect	either	misclassification	or	comorbid	FTD	and	AD	pathology.	Recently,	one	
such	mixed	pathology	 case	was	 reported	who	exhibited	 a	positive	 florbetapir	 PET	 scan	 in	 life	 and	
diffuse	 amyloid	 neuritic	 plaques	 throughout	 the	 cerebral	 cortex,	 thalamus	 and	 striatum	
accompanied	 by	 frontal	 and	 temporal	 cortex	 TDP-43	 inclusions	 at	 post-mortem	 (Serrano	 et	 al.,	
2014).	 Coexisting	 FTD	 and	 AD	 pathology	 is	more	 likely	 as	 people	 become	 older	 and	 so	 a	 positive	
amyloid	scan	is	less	helpful	as	age	increases,	particularly	as	amyloid	positivity	may	be	seen	a	number	
of	 years	 prior	 to	 symptoms	 of	 AD,	 and	 could	 therefore	 reflect	 prodromal	 AD	 rather	 than	
misdiagnosis.	
In	summary,	amyloid	imaging	demonstrates	confirmed	utility	in	differentiating	AD	from	FTD,	even	in	
the	 presence	 of	 overlapping	 clinical	 symptoms.	 Furthermore,	 it	 may	 prove	 useful	 in	 detecting	
atypical	FTD	presentations	with	underlying	AD	or	mixed	pathology.	 Its	value	 is	greatest	 in	younger	
individuals	 because	 of	 the	 high	 prevalence	 of	 amyloid	 plaques	 in	 older	 populations.	 However,	
amyloid	imaging	does	not	help	differentiate	tau	from	TDP-43	positive	pathologies.	Therefore,	tracers	
targeting	these	FTD-specific	pathologies	in	vivo	will	be	invaluable	for	FTD	research	and	stratification	
into	future	clinical	trials.	
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7.	Molecular	imaging	of	the	future:	the	place	of	tau	positron	emission	tomography	(PET)	
The	recent	development	of	PET	ligands	selective	for	tau	pathology	has	clear	potential	for	improving	
differential	 diagnosis	 in	 FTD	 as	 well	 as	 staging	 tau	 burden	 within	 the	 tauopathies.	 Furthermore,	
these	 tracers	may	provide	 important	 surrogate	outcome	measures	 for	 the	efficacy	of	 tau-targeted	
therapeutic	 interventions.	 There	 are	 several	 challenges	 for	 tau	 imaging:	 first,	 tau	 aggregates	 are	
mostly	 intracellular	 and	 so	 the	 tracer	 must	 successfully	 cross	 the	 blood–brain	 barrier	 and	 cell	
membrane	to	reach	its	target	(Villemagne	et	al.,	2015).	Furthermore,	the	six	different	isoforms	of	tau	
present	in	altered	combinations	in	different	clinical	phenotypes	and	tau	aggregates	are	subject	to	a	
variety	of	post-translational	modifications	leading	to	diverse	ultrastructural	conformations	(Sergeant	
et	al.,	2008).	The	candidate	tracers	must	therefore	be	nontoxic,	lipophilic	molecules	with	low	enough	
molecular	weight	to	cross	the	cell	membrane	and	must	reversibly	bind	with	high	affinity	to	a	variety	
of	tau	targets	in	a	selective	and	specific	manner	(Villemagne	&	Okamura,	2014).	It	is	also	preferable	
that	 these	 novel	 tau	 tracers	 be	 labelled	with	 radioisotopes	 that	 exhibit	 a	 longer	 half-life,	 such	 as	
fluorine-18	(≈2	hours)	to	facilitate	centralised	production	and	distribution	(Villemagne	&	Okamura,	
2016).	
Few	studies	have	been	performed	 in	FTD	as	yet.	A	novel	benzimidazole–pyrimidine	derivative,	 ¹⁸F-
T807	 (now	known	as	 18F-AV-1451)	has	been	described	 (Chien	et	 al.,	 2014;	 Xia	 et	 al.,	 2013),	which	
exhibits	greater	than	25-fold	selectivity	for	tau	over	Aβ	and	preliminary	findings	from	human	trials	
have	reported	cortical	retention	matching	known	distribution	of	tau	pathology	in	AD	subjects	(Chien	
et	al.,	2013,	2014).	Low	retention	in	white	matter	results	in	high	contrast	images,	ideal	for	visualising	
distribution	of	 tau	pathology	 (Villemagne	et	al.,	 2014).	 Studies	have	begun	 to	analyse	 tauopathies	
includeing	MAPT	mutation	carriers	with	18F-AV-1451	PET.	Preliminary	results	from	a	56-year-old	man	
with	 the	 P301L	 mutation	 demonstrates	 robust	 retention	 in	 characteristic	 frontotemporal	 regions	
(Ghetti	 et	 al.	 2015)	matching	 known	 tau	pathology	 in	 these	mutation	 carriers	 (Spina	et	 al.,	 2008).	
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This	 was	 detected	 three	 and	 a	 half	 years	 prior	 to	 the	 development	 of	 behavioural	 symptoms,	
suggesting	 sensitivity	 for	 early	 detection	 of	 abnormalities.	 However,	 it	 is	 important	 to	 note	 that	
there	are	reports	of	18F-AV-1451	also	binding	to	regions	not	known	for	tau	deposition	in	AD	patients	
as	 well	 as	 some	 discrepancies	 with	 in	 vitro	 studies	 reporting	 exclusive	 binding	 to	 paired	 helical	
filament-tau,	 whilst	 in	 vivo	 PET	 imaging	 demonstrating	 retention	 matching	 non-paired	 helical	
filament-tau	aggregate	distribution	(Villemagne	&	Okamura,	2016).	These	discrepancies	highlight	the	
need	for	future	post-mortem	validation	of	tau	tracers	to	move	this	promising	field	of	 investigation	
forward.	
In	summary,	tau	PET	imaging	represents	a	significant	advance	in	the	imaging	of	neurodegeneration.	
It	has	great	clinical	potential	for	improved	differential	diagnosis	and	elucidating	the	evolution	of	tau	
deposition	 in	 the	 brain.	 Its	 potential	 to	 improve	 stratification	 into	 future	 trials	 will	 be	 crucial	 to	
power	 detection	 of	 a	 positive	 result	 (given	 initial	 effect	 sizes	 are	 likely	 to	 be	 small),	 and	will	 also	
prove	 useful	 as	 a	 surrogate	 marker	 for	 evaluating	 tau-based	 therapies.	 Studies	 with	 autopsy	
confirmation	 as	 well	 as	 longitudinal	 investigations	 will	 be	 the	 next	 important	 steps	 for	 further	
validating	this	new	imaging	modality.	
	
8.	Multiplying	potential:	multimodal	imaging	and	advances	in	methodology	
The	combination	of	multiple	neuroimaging	 techniques	has	 recently	shown	promise	 for	providing	a	
more	 comprehensive	 picture	 of	 neurodegeneration.	 Initial	 investigations	 have	 demonstrated	
improved	differentiation	of	AD	from	bvFTD	patients	(Avants	et	al.,	2010)	using	combined	measures	
of	 MRI	 grey	 matter	 cortical	 thickness	 with	 DTI	 metrics	 of	 white	 matter	 abnormalities.	 Combined	
MRI/DTI	analyses	have	also	demonstrated	increased	sensitivity	and	specificity	for	discriminating	FTD	
and	 AD	 pathology	 (McMillan	 et	 al.,	 2012)	 as	 well	 as	 tau	 from	 TDP-43	 patients	 with	 autopsy	
confirmation	or	known	genetic	mutations	 (McMillan	et	al.,	2013).	Furthermore,	a	study	combining	
MRI,	DTI	and	ASL	found	important	differences	in	the	impact	of	grey	and	white	matter	structural	and	
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functional	abnormalities	between	AD	and	bvFTD	patients,	demonstrating	potential	value	to	improve	
differential	 diagnosis	 (Zhang	 et	 al.,	 2011).	 Recently,	 the	 application	 of	 combined	 MRI,	 DTI	 and	
resting-state	 fMRI	 in	 presymptomatic	 FTD	 mutation	 carriers	 showed	 different	 distributions	 of	
structural	 and	 functional	 connectivity	 changes	 in	 the	 frontotemporal	 grey	 and	 white	 matter	
structures	 in	 the	 absence	 of	 volumetric	 changes,	 providing	 valuable	 information	 about	 regions	 of	
earliest	changes	(Dopper	et	al.,	2013).	
	Alongside	 these	 developments,	 it	 is	 worth	 noting	 the	 emergence	 of	 increasingly	 sophisticated	
methods	for	modelling	and	analysing	these	combined	neuroimaging	datasets.	Using	combined	MRI	
grey	matter	 thickness	and	DTI,	 a	 recent	 study	 investigated	 the	optimal	neuroimaging	 classifiers	 to	
differentiate	FTD	and	AD	pathology	 (McMillan	et	al.,	 2014).	Neuroimaging	classifiers	are	based	on	
three	categories:	global	measures	(e.g.	ventricular	volume),	regional	anatomical	volumes	of	interest	
(VOIs)	 (e.g.	hippocampus)	and	a	new	technique	 for	data-driven	VOIs	called	eigenanatomy.	Broadly	
speaking,	 this	 identifies	 and	 rank-orders	 clusters	 of	 voxels	 so	 that	 only	 regions	 that	 explain	 the	
greatest	degree	of	 variance	 in	 the	 imaging	dataset	 are	 included.	 This	has	been	 shown	 to	 result	 in	
robust	 sets	 of	 predictors	 in	 classification	 studies,	 that	 are	 independent	 and	 not	 reliant	 on	
predetermined	anatomical	boundaries	(McMillan	et	al.,	2013a;	2013b).	Evaluations	of	classification	
accuracy	 using	 receiver	 operator	 characteristic	 analyses	 yielded	 the	 best	 results	 when	 combining	
data-driven	VOIs	and	multimodal	imaging	data	achieving	89%	sensitivity	and	89%	specificity	(AUC	=	
0.874)	 for	 pathology	 classification	 of	 AD	 or	 FTD	 based	 on	 CSF	 total	 tau/Aβ42	 findings.	 The	 same	
combination	 outperformed	 all	 others	 in	 the	 quantification	 of	 statistical	 power	 with	 the	 smallest	
estimated	sample	size	of	26	required	to	perform	accurate	classification.	This	provides	very	promising	
results	as	a	candidate	biomarker	for	screening	patients	for	entry	into	clinical	trials.	
	
9.	A	view	across	time:	longitudinal	investigations	of	rates	of	change	
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Whilst	 quantitative	 neuroimaging	 techniques	 have	 provided	 a	 wealth	 of	 information	 about	
neuroanatomical	 signatures	 in	 FTD,	 this	work	has	been	primarily	 cross-sectional.	Despite	 the	 clear	
benefits	 of	 longitudinal	 study	 design,	 relatively	 few	 studies	 have	 investigated	 how	 these	
neuroanatomical	 profiles	 differentially	 change	 over	 time	 and	 even	 fewer	 have	 reported	 rates	 of	
disease	progression	within	the	FTD	spectrum.	 Investigations	characterising	 longitudinal	 trajectories	
of	 change	 in	 FTD	are	 increasingly	 important	 as	we	move	 towards	 therapeutic	 trials	 in	 this	 patient	
population,	 not	 only	 to	 better	 characterise	 the	 evolution	of	 the	 disease,	 but	 to	 provide	 surrogate	
markers	 for	 evaluating	 the	 efficacy	 of	 treatment	 interventions	 on	 slowing	 these	 degenerative	
trajectories.	
Methods	 for	 quantifying	 brain	 atrophy	 rates	 from	 serial	 MRI	 are	 already	 currently	 employed	 as	
primary	outcome	measures	in	multiple	clinical	trials	in	AD	(Cash	et	al.,	2014)	and	are	likely	to	feature	
in	future	trials	enrolling	FTD	patients.	Therefore,	validation	within	this	population	is	critical.	Several	
studies	 have	 investigated	 rates	 of	 whole-brain	 loss	 and	 ventricular	 expansion	 across	 the	 clinical	
syndromes	(Chan	et	al.,	2001;	Gordon	et	al.,	2010;	Knopman	et	al.,	2009;	Rohrer	et	al.,	2008a,	2012).	
All	 have	 demonstrated	 significantly	 increased	 annual	 rates	 of	 change	 compared	with	 healthy	 age-
matched	controls,	employing	the	boundary	shift	integral	(Freeborough	&	Fox,	1997).	Reported	rates	
of	 annualised	whole-brain	 loss	have	varied	across	 studies	and	will	 need	 further	 validation	 in	 large	
well-characterised	cohorts.	However,	there	is	broad	agreement	across	studies	that	the	PPA	patients	
demonstrate	more	homogeneous	 rates	of	global	 change	compared	with	bvFTD	 (Chan	et	al.,	 2001;	
Gordon	et	al.,	2010;	Rohrer	et	al.,	2008a),	generally	 in	the	range	of	2–3%	of	baseline	brain	volume	
(Table	1).	Despite	this	global	consistency	in	PPA,	differences	in	hemispheric	and	lobar	changes	exist.	
One	 study	 suggests	 that	 left	 hemisphere	 rates	 are	 greater	 than	 right	 hemisphere	 rates	 for	 both	
svPPA	 and	 nfvPPA,	 with	 the	 left	 temporal	 lobe	 progressing	 fastest	 in	 svPPA	 and	 left	 frontal	 lobe	
fastest	in	nfvPPA	(Rohrer	et	al.,	2012).		
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Investigations	of	gene	positive	cases	show	a	similar	range	of	global	volumetric	changes	but	suggest	
that	MAPT	mutations	are	associated	with	a	mean	annual	rate	of	2.4%,	intermediate	between	those	
with	GRN	mutations,	who	exhibit	the	fastest	rate	of	loss	at	3.5%	and	C9orf72	whose	volumetric	rates	
are	 lowest	 at	 1.4%	 and	more	 in	 line	 with	 AD	 patients	 (Mahoney	 et	 al.,	 2012;	 Spina	 et	 al.,	 2008;	
Whitwell	et	al.,	2011c),	although	there	is	variability	within	each	group.	There	is	also	some	evidence	
for	an	acceleration	in	global	rates	of	change	in	patients	with	non-tau	pathology	as	disease	severity	
increases	 (Whitwell	 et	 al.,	 2008);	 however,	 extensive	 longitudinal	 investigations	 of	 patients	 with	
histopathological	confirmation	is	currently	lacking.	
Distinct	 neuroanatomical	 profiles	 from	 cross-sectional	 investigations	 indicate	 improved	 sensitivity	
may	be	achieved	with	regional	analysis	over	global	measures	to	capture	the	focal	changes	we	might	
expect	in	FTD.	However,	there	are	currently	very	few	studies	assessing	regional	longitudinal	rates	of	
change	 and	 their	 utility	 in	 improved	 diagnosis	 and	 tracking	 of	 pathogenic	 change.	 A	 recent	 study	
applying	an	automated	atlas-based	parcellation	on	serial	MRI	demonstrated	 that	 increased	annual	
atrophy	 in	 lateral	orbitofrontal	grey	matter	 regions	clearly	differentiated	bvFTD	 from	both	healthy	
controls	and	AD	patients,	whilst	 annual	 reductions	 in	 temporal	 lobe	white	matter	 structures	were	
also	 important	 in	 classification	 of	 bvFTD	 subjects	 (Frings	 et	 al.,	 2014).	 More	 recently,	 cortical	
thickness	 investigation	has	also	 implicated	the	orbitofrontal	gyrus,	with	significantly	 faster	 rates	of	
regional	thinning	in	bvFTD	compared	with	AD	and	controls	(Möller	et	al.,	2016).	Improved	sensitivity	
for	measurements	of	discrete	white	matter	tract	changes	in	the	right	cingulum	bundle	and	uncinate	
fasciculus	over	more	global	measures	has	been	recently	reported	in	a	longitudinal	DTI	investigation	
of	 bvFTD	 (Mahoney	 et	 al.,	 2015).	 Investigations	 in	 svPPA	 suggest	 improved	 sensitivity	 when	
measuring	disease	progression	with	temporal	lobar	volume	change	instead	of	hemispheric	or	whole-
brain	 measurements	 (Krueger	 et	 al.,	 2010;	 Rohrer	 et	 al.,	 2008a).	 In	 addition,	 a	 recent	 study	 of	
progressive	apraxia	of	speech	patients	(who	almost	exclusively	present	with	tau	pathology	at	post-
mortem	(Deramecourt	et	al.,	2009;	Dickson	et	al.,	2010)),	demonstrated	that	annual	rates	of	atrophy	
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in	the	precentral	and	supplementary	motor	areas	outperformed	other	regional	and	more	global	MRI	
measures	(Whitwell	et	al.,	2015).		
The	 utility	 of	 these	 rates	 of	 change	markers,	 based	 on	 estimated	 sample	 sizes	 to	 demonstrate	 a	
relevant	therapeutic	effect,	varies	accordingly	across	method	and	patient	subtype	(Table	2).	Sample	
sizes	 are	 generally	 more	 feasible	 in	 the	 PPA	 syndromes	 given	 the	 heterogeneity	 of	 bvFTD.	 This	
highlights	 the	 importance	 of	 improved	 stratification	 into	 trials	 and	 increasingly	 targeted	 regional	
measures	of	longitudinal	change	in	these	focal	disease	populations.	Future	confirmation	of	rates	of	
change	 in	 large	 well-characterised	 cohorts	 is	 required	 to	 harmonise	 these	 longitudinal	 markers.	
However	it	is	promising	to	note	that	despite	variability,	many	measures	do	produce	feasible	samples	
sizes	of	50-100	patients	per	treatment	arm.	
	
10.	A	view	back	in	time:	presymptomatic	investigations	
A	 relatively	 high	 proportion	 of	 FTD	 cases	 are	 familial,	 which	 provides	 the	 potential	 for	 early	
(presymptomatic)	intervention.	Presymptomatic	genetic	studies	have	suggested	differential	areas	of	
earliest	 change	 across	 the	 genetic	 subtypes.	 Validating	 markers	 of	 these	 prodromal	 changes	 is	
essential	 for	 future	 trial	design,	because	 interventions	 in	neurodegenerative	conditions	will	 ideally	
be	 prior	 to	 clinical	 symptoms	when	 only	minimal	 irreversible	 neuronal	 loss	 has	 occurred	 and	 the	
majority	of	cognitive	function	remains	intact.	
Early	studies	of	at-risk	mutation	carriers	reported	inconsistent	neuroimaging	findings.	Some	showed	
evidence	of	grey	matter	atrophy	in	the	different	mutation	types	(Janssen	et	al.,	2005;	Rohrer	et	al.,	
2008b,	 2015;	 Spina	 et	 al.,	 2008),	 whilst	 others	 found	 no	 structural	 MRI	 abnormalities	 prior	 to	
symptom	onset	 (Borroni	 et	 al.,	 2008;	Dopper	 et	 al.,	 2013;	Whitwell	 et	 al.,	 2011b).	 Some	of	 these	
studies	did	find	abnormalities	with	the	use	of	other	 imaging	modalities,	suggesting	that	changes	 in	
structural	 and	 functional	 connectivity	may	precede	 the	 development	 of	 atrophy	 and	 demonstrate	
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greater	 utility	 as	 early	markers.	 Using	 DTI,	 reduced	 FA	 in	 the	 left	 uncinate	 fasciculus	 and	 inferior	
fronto-occipital	fasciculus	was	detected	in	four	at-risk	GRN	patients	compared	with	controls	(Borroni	
et	 al.,	 2008).	 A	 larger	 DTI	 study	 also	 showed	 decreased	 FA	 in	 the	 right	 inferior	 fronto-occipital	
fasciculus	 alongside	white	matter	 abnormalities	 of	 the	 right	 anterior	 and	 superior	 corona	 radiata,	
anterior	 thalamic	 radiation,	 superior	 longitudinal	 fasciculus	 and	 internal	 capsule.	 In	 comparison,	
presymptomatic	 MAPT	 carriers	 demonstrated	 more	 widespread	 white	 matter	 abnormalities	
throughout	 frontotemporal	 tracts	 (Dopper	 et	 al.,	 2013),	 in	 line	 with	 regions	 implicated	 in	
symptomatic	MAPT	patients.	Using	resting	state	fMRI,	this	same	study	reported	reduced	functional	
connectivity	 in	 the	 anterior	 midcingulate	 cortex	 (part	 of	 the	 salience	 network)	 for	 GRN	 carriers	
(Dopper	 et	 al.,	 2013),	whereas	others	 have	 shown	 increased	 functional	 connectivity	 in	 the	medial	
prefrontal	 cortex	 (Borroni	et	al.,	 2012),	or	no	 functional	 connectivity	 changes	at	all	 (Pievani	et	al.,	
2014).	In	MAPT	mutations,	reduced	connectivity	in	the	lateral	temporal	and	prefrontal	regions	(part	
of	the	DMN)	has	been	reported	(Whitwell	et	al.,	2011b),	whilst	others	have	failed	to	find	significant	
connectivity	changes	with	these	presymptomatic	carriers	(Dopper	et	al.,	2013).	
As	is	the	nature	of	investigating	rare	forms	of	a	rare	disease,	a	major	limitation	contributing	to	these	
inconsistencies	 in	 presymptomatic	 research	 is	 small	 study	 sizes.	 To	 overcome	 this,	 the	 Genetic	
Frontotemporal	dementia	Initiative	(GENFI)	was	launched	to	assess	the	feasibility	of	an	international	
study	applying	uniform	assessment	protocols	across	multiple	sites	(Rohrer	et	al.,	2015).	Preliminary	
findings	from	GENFI	have	shown	significant	differences	in	cortical	and	subcortical	volumes	between	
presymptomatic	carriers	and	non-carriers	greater	than	10	years	before	expected	clinical	onset.	Early	
changes	were	seen	in	the	insula,	followed	closely	by	the	temporal	and	then	frontal	lobes	(Figure	7).	
Distinct	 temporal	 and	 spatial	 profiles	 were	 seen	 with	 the	 different	 genetic	 causes.	 For	 MAPT	
mutation	 carriers,	 differences	 first	 emerged	 in	 the	 hippocampus	 and	 amygdala	 (15	 years	 before	
expected	onset),	 followed	by	 temporal	 lobe	 (10	years	prior	 to	expected	onset)	and	 insula	 (5	years	
prior).	 In	contrast,	GRN	mutation	carriers	exhibited	differences	to	non-carriers	initially	in	the	insula	
(15	years	before	onset),	the	temporal	and	parietal	lobes	(both	10	years	before	expected	onset)	and	
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then	striatum	(5	years	prior),	with	clear	evidence	of	asymmetry	emerging	5	years	before	expected	
symptoms.	The	C9orf72	 carriers	presented	with	yet	another	distinct	neuroanatomical	profile,	with	
subcortical	 regions	 including	 the	 thalamus,	 the	 insula	 and	 posterior	 cortical	 areas,	 differing	 from	
non-carriers	 25	 years	 before	 expected	 symptom	 onset.	 This	 was	 followed	 by	 the	 frontal	 and	
temporal	 lobes,	 both	 20	 years	 prior	 to	 onset	 and	 the	 cerebellum	 10	 years	 before	 expected	
symptoms.	
These	regional	profiles	are	consistent	with	previous	neuroimaging	studies	in	symptomatic	mutation	
carriers,	 but	 show	 significant	 robust	 changes	much	earlier	 than	 suggested	previously.	 As	with	 any	
cross-sectional	 analysis,	 the	 apparent	 temporal	 and	 spatial	 sequence	 of	 disease	 progression	 is	
inferred	 from	 different	 patients	 in	 each	 stage	 of	 the	 presymptomatic	 spectrum.	 A	 more	 robust	
picture	 of	 structural	 progression	 in	 these	 cortical	 and	 subcortical	 regions	 will	 be	 clarified	 when	
familial	 FTD	 studies	 report	 longitudinal	 data.	 Previous	 work	 suggests	 that	 connectivity	 changes	
precede	 volumetric	 changes	 and	 thus	 the	 inclusion	 of	 DTI	 and	 resting-state	 fMRI	 into	 the	 GENFI	
protocol	 will	 provide	 valuable	 information	 about	 the	 staging	 of	 these	 structural	 and	 functional	
changes	 presymptomatically.	 In	 addition,	 tau	 PET	 imaging	 shows	 great	 promise	 and	 will	 be	
invaluable	 for	 visualising	 and	 staging	 the	 evolution	 of	 pathological	 tau	 deposition	 throughout	 all	
stages	of	diseases	in	MAPT	cohorts.	
	
11.	A	view	to	the	future:	symptomatic	trial	interventions	
The	 past,	 present	 and	 future	 of	 FTD	 clinical	 trials	 is	 reviewed	 in	 depth	 elsewhere	 in	 this	 issue,	
however	a	number	of	insights	from	neuroimaging	in	AD	trials	and	preliminary	work	in	FTD	are	worth	
noting.	 There	 are	 currently	 several	 trials	 targeting	 genetic	 FTD	 cases	 currently	 recruiting	 (FORUM	
https://clinicaltrials.gov/ct2/show/NCT02149160,	 and	 TauRx	
https://clinicaltrials.gov/ct2/show/NCT02245568?term=taurx&rank=2),	 and	 the	 success	of	DIAN-TU	
(the	 Dominantly	 Inherited	 Alzheimer	 Network	 Trial)	 confirms	 the	 feasibility	 of	 international	
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recruitment	into	presymptomatic	phase	II/III	randomised	treatment	trials,	incorporating	multimodal	
imaging	endpoints.	
With	 continued	 development	 of	 novel	 and	more	 sensitive	 imaging	 techniques,	 the	 beneficial	 role	
they	 can	 play	 in	 facilitating	 the	 design,	 enrolment	 and	 in	 assessing	 safety	 and	 efficacy	 in	 future	
clinical	trials	 is	expanding.	Presymptomatic	studies	suggest	that	neuroimaging	can	provide	valuable	
markers	 of	 volumetric	 change	 up	 to	 20	 years	 prior	 to	 expected	 symptom	 onset.	 The	 utility	 of	
structural	and	functional	connectivity	measure	to	contribute	further	to	our	understanding	of	earliest	
detectable	changes	is	becoming	clearer	and	the	advent	of	tau	PET	imaging	may	shift	the	window	of	
in	 vivo	 pathogenic	 investigation	 even	 earlier.	Multimodal	 imaging	will	 be	 an	 important	 feature	 of	
future	clinical	trials	and	its	application	in	presymptomatic	cohorts	will	assist	in	identifying	the	initial	
sites	of	vulnerability	and	in	staging	subsequent	distribution	of	pathological	damage	in	the	prodromal	
stages	 of	 these	 diseases.	With	 this	 in	 place,	 the	 optimal	 point	 of	 therapeutic	 intervention	 can	 be	
incorporated	 into	future	trial	designs	to	 intervene	when	the	minimum	of	 irreversible	neuronal	 loss	
has	 occurred	 whilst	 still	 maintaining	 enough	 power	 to	 detect	 a	 positive	 treatment	 effect	 with	
inevitably	relatively	small	study	populations.	
A	 critical	 trial	 design	 issue	 is	 the	 correct	 enrolment	 and	 stratification	 of	 patients	 who	 have	 the	
pathology	 specifically	 targeted	 by	 the	 intervention.	 This	 has	 been	 a	 key	 issue	 in	 many	 AD	 trials,	
which	 based	 enrolment	 primarily	 on	 clinical	 presentation	without	 corroborating	 amyloid	 imaging.	
Inclusion	of	patients	without	AD	pathology	severely	weakens	the	power	of	 these	studies	to	detect	
treatment	 effects.	 The	 same	 will	 be	 true	 for	 FTD	 trials	 and	 a	 combination	 of	 molecular	 imaging	
confirmation,	genotyping	and	probabilistic	matching	of	 the	expected	neuroanatomical	signature	of	
presenting	patients	 in	 line	with	pathology-confirmed	 investigations	would	aid	 in	excluding	patients	
with	features	indicative	of	other	neurodegenerative	conditions.	
Neuroimaging	markers	will	provide	means	of	assessing	safety	by	screening	for	adverse	events.	This	
has	 shown	value	 in	 the	detection	of	amyloid-relating	 imaging	abnormalities	as	a	 response	 to	anti-
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amyloid	immunotherapy	trials	in	AD	(Sperling	et	al.,	2013).	In	addition,	combining	available	imaging	
will	provide	measures	of	treatment-related	change	to	molecular	composition	(with	tau	and	amyloid	
PET),	 downstream	effects	on	 functional	 and	 structural	 connectivity,	 as	well	 as	 changes	 in	 regional	
and	global	measures	of	neuronal	loss.	Validation	of	each	modality	and	chosen	metric	will	be	critical	
in	the	specific	population	targeted	by	the	 intended	treatment	prior	to	 implementation.	Ultimately,	
the	 absolute	 utility	 of	 these	 markers	 can	 only	 be	 confirmed	 in	 the	 presence	 of	 measuring	 a	
successful	 disease-modifying	 treatment.	Until	 then,	 continued	 focus	on	 validating	 these	promising	
neuroimaging	biomarkers	in	all	stages	of	disease	from	presymptomatic,	through	symptomatic	stages	
of	 genetic	 and	 sporadic	 presentations	 to	 patients	 with	 histopathological	 confirmation	 will	 be	
invaluable.	
	
Conclusions	
The	field	of	neuroimaging	in	FTD	has	made	significant	advances	over	the	past	five	years.	These	have	
been	 driven	 by	 improved	 understanding	 of	 the	 underlying	 genetics	 and	 pathology,	 alongside	
improvements	 in	 imaging	 and	 in	 particular	 the	 development	 of	molecular	 imaging	 of	 tau.	With	 a	
renewed	focus	on	longitudinal	investigations,	the	use	of	combined	imaging	modalities	on	large	well-
characterised	 cohorts,	 and	 the	 development	 of	 therapeutic	 trials	 that	 incorporate	 multi-modal	
imaging	the	next	five	years	hold	promise	for	even	greater	insights	from	imaging	in	FTD.		
	 	
	 25	
Figures	and	Tables	
Figure	 1.	 Characteristic	 patterns	 of	 grey	 matter	 atrophy	 in	 the	 four	 major	 clinical	 FTD	 subtypes,	
overlaid	 on	 a	 rendered	 3D	 surface	 of	 the	 Montreal	 Neurological	 Institute	 Template	 brain.	
Representative	 coronal,	 sagittal	 and	 axial	 slices	 are	 displayed	 in	 the	 first,	 second	 and	 third	 rows	
respectively.	Images	reproduced	from	Agosta	et	al.,	2012a.	
Figure	 2.	 Coronal	 T1	 volumetric	 MR	 images	 displaying	 characteristic	 patterns	 and	 distribution	 of	
regional	volume	loss	for	each	of	the	main	genetic	and	pathological	subtypes	of	FTD.		
Figure	 3.	 Representative	 regional	 distribution	of	 the	 salience,	 default	mode	 and	 executive	 control	
functional	 networks.	 Abbreviations:	 dACC,	 dorsal	 anterior	 cingulate	 cortex;	 VMPFC,	 ventromedial	
prefrontal	 cortex;	 PCC,	 posterior	 cingulate	 cortex;	 PrC,	 precuneus;	 DLPFC,	 dorsolateral	 prefrontal	
cortex;	 IC,	 insular	 cortex;	 sPL,	 superior	parietal	 lobule;	 and	FEF,	 Frontal	 Eye	Fields.	 Image	adapted	
from	Hoeft	et	al.,	2012.	
Figure	4.	Main	white	matter	tracts	affected	in	bvFTD,	svPPA,	nfvPPA,	CBD	and	AD.	Images	adapted	
from	Catani	&	Mesulam,	2008.	
Figure	5.	Distribution	of	typical	hypometabolism	profiles	acquired	using	FDG-PET	in	AD	patients	and	
patients	 with	 frontal	 and	 temporal	 FTD.	 Patterns	 are	 presented	 as	 z-score	 maps	 demonstrating	
voxels	 of	 significant	 hypometabolism	 compared	 with	 healthy	 controls.	 The	 focal	 frontal	 and	
temporal	 pattern	 of	 hypometabolism	 in	 the	 FTD	 subgroups	 can	 be	 clearly	 distinguished	 from	 the	
distributed	and	posterior	profile	of	temporoparietal	hypometabolism	evident	in	AD.	ANT	=	anterior;	
INF	 =	 inferior;	 LAT	 =	 lateral;	 MED	 =	 medial;	 POST	 =	 posterior;	 SUP	 =	 superior.	 Reproduced	 from	
Bohnen	et	al.,	2012.	
Figure	6.	Representative	examples	of	Pittsburgh	Compound	B	(PIB)	PET	images.	A)	PiB-PET	negative	
retention	indicating	the	lack	of	amyloid	deposition.	This	is	characteristic	of	bvFTD,	svPPA	and	nfvPPA	
subjects.	B)	and	C)	demonstrate	images	from	lvPPA	cases	who	had	a	positive	scan	(arrows	indicate	
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the	 cortical	 regions	 in	 B)	 with	 a	 PiB-standardized	 uptake	 values	 ratio	 higher	 than	 1.50)	 and	 D)	 a	
positive	 scan	 from	 a	 typical	 AD	 case.	 SUVR	 =	 standardized	 uptake	 value	 ratio.	 Image	 reproduced	
from	Leyton	et	al.,	2011.	
Figure	 7.	 Graphs	 of	 expected	 trajectories	 of	 lobar	 change	 based	 on	 the	 standardised	 difference	
between	mutation	 carriers	 and	 non-carriers	 in	 cortical	 grey	 matter	 volumetric	 imaging	 measures	
versus	estimated	years	from	expected	symptom	onset.	Reproduced	from	Rohrer	et	al.,	2015.	
	
Table	1.	 Summary	of	 annualized	global	 and	 regional	 atrophy	 rates	 (expansion	 rates	 for	 ventricles)	
from	previously	published	studies.	
Table	2.	Summary	of	previously	published	sample	size	estimates	from	studies	 investigating	the	use	
of	 imaging	biomarkers	 in	 future	clinical	 trials	of	FTD.	The	estimates	represent	the	sample	size	that	
would	be	required	per	trial	arm	to	detect	the	stated	%	treatment	effect	from	measures	of	rates	of	
change.	The	power	(β)	and	statistical	threshold	(α)	used	to	calculate	the	sample	size	for	each	study	
are	 listed	 individually	for	every	publication,	as	are	additional	 factors	such	as	controlling	for	normal	
aging	 and	 expected	 attrition	 rate	 from	 the	 putative	 trial.	 FA	 (fractional	 anisotropy);	 MD	 (mean	
diffusivity);	RD	(radial	diffusivity);	AD	(axial	diffusivity).	*PPAOS	for	Whitwell	et	al,	2015.	
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Table	1	
Publication	and	cohort	 Measure	 bvFTD	 svPPA	 nfvPPA	 lvPPA	 Controls	 MAPT	 GRN	 C9orf72	
Chan	et	al.,	(2001)	
bvFTD	(n=17),	PPA	(n=13;	12	
svPPA,	1	nfvPPA),	controls	(n=27)	
Whole	brain	(%)	 3.7	(2.5)	 2.5	(1.0)	
		
0.5	(0.4)	
		 		 		
Rohrer	et	al.,	(2008a)	
svPPA	(n=21),	controls	(n=20)	
Whole	brain	(ml)	 		 27.4	(16.0)	 		 		 4.4	(4.1)	 		 		 		
Ventricular	expansion	(ml)	 		 6.9	(3.8)	 		 		 0.7	(1.0)	 		 		 		
Left	temporal	lobe	(ml)	 		 2.8	(1.2)	 		 		 0.4	(0.6)	 		 		 		
Right	temporal	lobe	(ml)	 		 3.9	(1.7)	 		 		 0.4	(0.8)	 		 		 		
Left	hippocampus	(ml)	 		 0.14	(0.08)	 		 		 0.02	(0.05)	 		 		 		
Right	hippocampus	(ml)	 		 0.18	(0.10)	 		 		 0.004	(0.03)	 		 		 		
Knopman	et	al.,	(2009)	
bvFTD	(n=34),	svPPA	(n=16),	
nfvPPA	(n=17),	lvPPA	(n=9),	
controls	(n=15)	
Whole	brain	(%)	 1.6	(1.1)	 1.7	(1.0)	 1.6	(0.9)	 2.1	(1.0)	 0.4	(0.4)	 		 		 		
Ventricular	expansion	(ml)	 11.2	(6.8)	 13.2	(5.4)	 11.0	(4.4)	 14.8	(5.6)	 2.3	(1.4)	
		 		 		
Gordon	et	al.,	(2010)	
bvFTD	(n=11),	svPPA	(n=11),	
nfvPPA	(n=10),	controls	(n=24)	
Whole	brain	(%)	 1.4	(1.5)	 2.6	(1.6)	 2.9	(0.9)	 		 0.1	(0.5)	 		 		 		
Ventricular	expansion	(ml)	 5.5	(6.7)	 7.1	(4.9	 5.6	(3.8)	 		 0.5	(1.1)	 		 		 		
Rohrer	et	al.,	(2010b)	
MAPT	(n=6),	GRN	(n=4)	 Whole	brain	(%)		
		 		 		 		 		 1.4	(0.9	to	1.9)	 3.4	(2.8	to	4.0)	 		
Whitwell	et	al.,	(2011c)	
MAPT	(n=12),	GRN	(n=8),	Control	
(n=20)	
Whole	brain	(%)	 		 		 		 		 0.2	(0.1	to	0.5)	 2.4	(1.9	to	2.8)	 3.5	(2.8	to	4.2)	 		
Hippocampus	(%)		 		 		 		 		 0.0	(-0.3	to	0.3)	 7.8	(3.9	to	12)	 6.5	(1.7	to	11)	 		
Rohrer	et	al.,	(2012)	
svPPA	(n=17),		nfvPPA	(n=18),		
controls	(n=14)	
Whole	brain	(%)	 		 2.5	(1.5)	 2.6	(1.2)	 		 0.4	(0.4)	 		 		 		
Ventricular	expansion	(ml)	 		 6.9	(4.4)	 6.6	(3.4)	 		 0.7	(1.2)	 		 		 		
Frontal	lobe	(%,	Left;	Right)	 	 4.3	(2.0);	2.8	(2.5)	 5.7	(2.8);	4.5	(2.3)	 	 	 	 	 	
Temporal	lobe	(%,	Left;	Right)	 	 7.1	(2.3);	6.6	(2.9)	 5.3	(3.6);	3.4	(3.5)	 	 	 	 	 	
Parietal	lobe	(%,	Left;	Right)	 	 3.5	(2.9);	2.0	(2.9)	 4.3	(2.3);	3.5	(3.2)	 	 	 	 	 	
Occipital	lobe	(%,	Left;	Right)	 	 1.8	(3.1);	1.3	(2.9)	 1.0	(3.0);	1.2	(3.8)	 	 	 	 	 	
Mahoney	et	al.,	(2012)	
C9orf72	(n=6),	controls	(n=15)	
Whole	brain	(%)	 		 		 		 		 0.4	(0.3)	 		 		 1.4	(1.6)	
Ventricular	expansion	(ml)	 		 		 		 		 0.7	(06)	 		 		 3.2	(2.0)	
Frings	et	al.,	(2014)	
bvFTD	(n=15),	controls	(n=10)	
	
Lateral	Orbitofrontal	gyrus	(%)	 5.6	(4.5)	 		 		 		 1.0	(1.7)	 		 		 		
Hippocampus	&	Amygdala	(%)	 3.6	(3.2)	 		 		 		 1.0	(0.8)	 		 		 		
Insula	(%)	 3.6	(2.9)	 		 		 		 0.7	(0.9)	 		 		 		
Mahoney	et	al.,	(2015)	
bvFTD	(n=23),	MAPT	(n=8),	
C9orf72	(n=4),	controls	(n=18)	
Whole	brain	(ml)	 15.2	(10.4)	
		 		 		
5.2	(6.7)	 15.7	(6.7)	
		
14.4	(17.8)	
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Table	2	
	
Publication,	and	cohort	 Measure	 bvFTD	 svPPA	 nfvPPA*	 lvPPA	
Rohrer	et	al.,	(2008a)	
β=	90%,	α=0.05	
svPPA	(n=20,	9	FTLD-U	confirmed)	 	
		 	 		 		
30%	treatment	effect	
Whole	brain		 		 118	 		 		
Ventricles	 		 89	 		 		
Left	temporal	lobe		 		 60	 		 		
Right	temporal	lobe		 		 55	 		 		
Left	hippocampus	 		 104	 		 		
Right	hippocampus	 		 81	 		 		
Knopman	et	al	(2009)	
β=	80%,	α=0.05,	correcting	for	26%	attrition	rate	
bvFTD	(n=34),	svPPA	(n=16),	nfvPPA	(n=17),	lvPPA	(n=9)	 	 	 	 	 	
25%	treatment	effect	
Whole	brain		 165	 135	 105	 81	
Ventricles	 127	 58	 55	 50	
40%	treatment	effect	
Whole	brain		 66	 54	 42	 32	
Ventricles	 51	 24	 23	 20	
Gordon	et	al	(2010)	
β=	80%,	α=0.05,	adjusting	for	control	rates	and	annual	attrition	of	10%	
bvFTD	(n=11),	svPPA	(n=11),	nfvPPA	(n=10)	 	 	 	 	
		
25%	treatment	effect	
Whole	brain		 360	 115	 26	 		
Ventricles	 495	 157	 152	 		
40%	treatment	effect	
Whole	brain		 141	 45	 10	 		
Ventricles	 193	 61	 59	 		
Rohrer	et	al	(2012)		
β=	90%,	α=0.05,	adjusting	for	control	rates	
svPPA	(n=17),	nfvPPA	(n=18)	 	
		 	 	 		
30%	treatment	effect	
Whole	brain		 		 120	 70	 		
Ventricles	 		 118	 78	 		
Mahoney	et	al	(2015)	
β=	80%,	α=0.05,	adjusting	for	control	rates	
bvFTD	(n=19,	including	8	MAPT	and	4	C9orf72	mutations)	
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20%	treatment	effect	
Whole	brain	 507	 		 		 		
Right	cingulum	bundle	(FA)	 276	 		 		 		
Right	cingulum	bundle	(MD)	 1,031	 		 		 		
Right	uncinate	fasciculus	(RD)	 531	 		 		 		
Right	uncinate	fasciculus	(AD)	 1,229	 		 		 		
40%	treatment	effect	
Whole	brain	 127	 		 		 		
Right	cingulum	bundle	(FA)	 69	 		 		 		
Right	cingulum	bundle	(MD)	 258	 		 		 		
Right	uncinate	fasciculus	(RD)	 133	 		 		 		
Right	uncinate	fasciculus	(AD)	 308	 		 		 		
Whitwell	et	al	(2015)		
β=	80%,	α=0.05	
Progressive	apraxia	of	speech	(n=24)	 	
		 		 		 		
20%	treatment	effect	
Precentral		 		 		 38	 		
Supplementary	motor	area	 		 		 49	 		
Whole	brain		 		 		 116	 		
Ventricles	 		 		 118	 		
Superior	frontal	lobe	 		 		 163	 		
Superior	parietal	lobe	 		 		 224	 		
Striatum	 		 		 266	 		
Midbrain	 		 		 	380	 		
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